Autologous Transplantation for Older Adults with AML

Cancers
Beatrice U MuellerThomas Pabst

Abstract

While the majority of patients with acute myeloid leukemia (AML) are above the age of 65 years at diagnosis, the outcome of older AML patients remains disappointing. Even if standard intensive chemotherapy induces morphologic complete remission (CR1), relapses in older AML patients are common leading to poor long-term survival outcomes. Since autologous hematopoietic stem cell transplantation (HCT) offers distinct anti-leukemic effectiveness while avoiding graft-versus-host disease associated with allogeneic transplantation, it represents an option for consolidation treatment in selected older AML patients. However, prospective studies in older AML patients assessing the benefit of autologous HCT compared to chemotherapy consolidation or allogeneic transplantation are lacking. Consequently, clinicians face the dilemma that there is considerable ambiguity on the most appropriate consolidation treatment for older AML patients in CR1. This review highlights the possible role of autologous HCT for consolidation in older AML patients reaching CR1 after induction treatment.

References

Jul 14, 2001·Journal of Chemotherapy·I LandiniP A Bernabei
Oct 22, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nathan GunnCharles Linker
Mar 17, 2007·Hematological Oncology·Felicetto FerraraSalvatore Palmieri
May 14, 2008·Reviews on Recent Clinical Trials·Felicetto Ferrara, Antonio Pinto
Jan 27, 2009·Bone Marrow Transplantation·M HeizmannM J Bargetzi
Jan 30, 2009·Journal of the National Comprehensive Cancer Network : JNCCN·Jeffrey E Lancet, Sergio Giralt
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Norbert-Claude GorinUNKNOWN Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation
Sep 25, 2009·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group
Mar 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian L McCluneSergio Giralt
Aug 13, 2011·Blood·L Bik ToKirsten E Herbert
Sep 29, 2011·Blood·Edo VellengaUNKNOWN Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)
Dec 25, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthias StelljesThomas Büchner
Nov 1, 2008·International Journal of Stem Cells·Mi Jung KimJae Suk Chang
Dec 18, 2014·Blood·Gert Ossenkoppele, Bob Löwenberg
Feb 1, 2015·Haematologica·Norbert-Claude GorinUNKNOWN Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Sep 4, 2016·Journal of Hematology & Oncology·Francesco SaraceniUNKNOWN Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)
Feb 15, 2017·Bone Marrow Transplantation·V BlumT Pabst

❮ Previous
Next ❯

Citations

Mar 30, 2021·Journal of Internal Medicine·V Lj Lazarevic
May 12, 2021·Stem Cell Reviews and Reports·Andrea M PattersonChristie M Orschell

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.